Ribon Therapeutics
2015
FOUNDED
PRIVATE
STATUS
21-30
EMPLOYEES
Series B
LATEST DEAL TYPE
$65M
LATEST DEAL AMOUNT
9
INVESTORS
Description
Developer of novel therapeutics targeting monoADP-ribosylating PARPs for cancer designed to block cancer cells' fundamental ability to survive under stress. The company is creating an integrated technology platform to interrogate monoPARPs and to discover and develop, small molecule medicines that selectively target monoPARPs to treat cancer.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 99 Hayden Avenue
- Building D, Suite 100
- Lexington, MA 02421
- United States
+1 (617) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Ribon Therapeutics’s full profile, request a free trial.
Ribon Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 04-Jan-2019 | $65M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 1. Early Stage VC (Series A) | 10-Oct-2017 | 000.00 | 000.00 | 000.00 | Completed | Stealth |
Ribon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Ribon Therapeutics Competitors (23)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Jounce Therapeutics | Failed Transaction (M&A) | Cambridge, MA | 000 | 00000 | 000000&0 | |
| 00000000 | Venture Capital-Backed | Uppsala, Sweden | 00 | 0000000000 | ||
| 0000000 0000000000 | Formerly VC-backed | Richmond, CA | 000 | 000.00 | 00000000 | 000.00 |
| 00000000 | Angel-Backed | Culver City, CA | 00000 | 000000000000 | 00000 | |
| 000000 000000 | Formerly VC-backed | Seattle, WA | 00 | 00000 | 000000&0 | 00000 |
Ribon Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Celgene | Corporation | Minority | 000 0000 | 000000 0 | ||
| Johnson & Johnson Innovation - JJDC | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Deerfield Management | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Euclidean Capital | Other | Minority | 000 0000 | 000000 0 |
Ribon Therapeutics Executive Team (8)
You’re viewing 5 of 8 executives. Get the full list »Ribon Therapeutics Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Anja König Ph.D | Novartis Venture Fund | Board Member | 000 0000 | |
| Cameron Wheeler Ph.D | Deerfield Management | Board Member | 000 0000 | |
| James Audia Ph.D | Self | Board Member | 000 0000 | |
| Jonathan Root MD | US Venture Partners | Board Member | 000 0000 | |
| Laurence Lasky Ph.D | The Column Group | Board Member | 000 0000 |